Browsing: sanofi-aventis

Patients hoping for a new alternative to the blockbuster blood thinner Plavix will have to wait a bit longer for a verdict on a promising candidate.

ImmunoGen has licensed its anti-cancer technology to Amgen for an upfront payment of $1 million.

If the past week is any indication, big pharma is showing that it is willing to pay for biotech innovation.

Micromet has licensed one of its cancer-fighting antibody candidates to Sanofi-Aventis in a $477 million deal.